View all data FOR FREE!
Create an account today, no credit card required.
| Issue Type | XXXX |
|---|---|
| Country | United Kingdom |
| Industry | XXXX |
| Region | XXXX |
| Maturity Date | 2031-03-25 |
| Par Value | 2000 |
| Callable | XXXX |
| Next Call Date | XXXX |
| Call Type | XXXX |
| Call Price (%) | XXXX |
| Series | XXXX |
| Class | XXXX |
| Maturity Structure | XXXX |
| Amount Outstanding (mil) | 600.00 |
| Coupon | 4.45 |
|---|---|
| Coupon Type | XXXX |
| Coupon Frequency | XXXX |
| First Coupon Date | XXXX |
| Last Coupon Date | XXXX |
| Sinking Fund | XXXX |
|---|---|
| Security | XXXX |
| Subordination | XXXX |
| Debt Type | XXXX |
| Issue Date | XXXX |
|---|---|
| Dated Date | XXXX |
| Issue Size (mil) | 600.000 |
| Min. Piece | XXXX |
| Min. Increment | XXXX |
This Royalty Pharma plc corporate note has a 4.45% fixed rate coupon paid on a semi-annual basis. It was issued on September 16, 2025 with an issue size of 600.00 million USD and matures on March 25, 2031 with a last coupon date of September 25, 2030. |
Royalty Pharma plc, founded in 1996 and headquartered in New York City, is a leading buyer of royalty interests in innovative biopharmaceutical products. The company aims to provide investors with access to diverse, revenue-generating assets from established therapies and promising late-stage product candidates. Royalty Pharma's portfolio includes royalties from major pharmaceuticals such as AbbVie’s Imbruvica and Vertex's cystic fibrosis treatments, illustrating its strategic focus on high-value healthcare investments.